Physician

Zarmeena Ali, MD

According to 2025 Medicare claims, Zarmeena Ali, MD (NPI: 1538137708) practices rheumatology in the Columbus, GA-AL market, with the plurality of this provider's patient population coming from Muscogee, GA. This provider's primary affiliated billing organization is ARTICULARIS HEALTHCARE GROUP INC. (NPI: 1730770421; TIN: 571099718) and primary practice location at 36832-5906. Ali is affiliated with the Southeastern Health Partners (ACO ID: A3325), participating under the MSSP model.

Ali's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 248 traditional Medicare patients, billed 52,923 HCPCS/CPT codes, and received $586,132 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 5,853 prescription claims across 583 beneficiaries totaling $7,281,191 in drug costs, led by Rinvoq (Upadacitinib). 2021 DME data shows 22 claims. Open Payments data shows 56 records totaling $1,203. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $43,498 to $586,132. Similarly, Part D prescription costs have moved sharply higher in recent years, from $289,294 to $7,281,191. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	251	676	$43,498
2018	343	816	$45,327
2019	310	745	$40,877
2020	272	745	$34,954
2021	272	9,015	$240,025
2022	227	30,788	$481,530
2023	233	57,049	$524,542
2024	248	52,923	$586,132

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	198	953	$289,294
2018	385	2,937	$2,066,802
2019	399	3,859	$3,555,619
2020	411	4,444	$5,415,979
2021	435	4,162	$4,868,196
2022	469	4,973	$6,438,753
2023	503	5,605	$7,247,527
2024	583	5,853	$7,281,191

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$33
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	22	$743
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	62	62	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	158	264	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	49	55	$54
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	45	119	$51
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	137	213	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	168	5,040	$1,070,697
Enbrel Sureclick	Etanercept	138	3,892	$1,053,915
Humira(Cf) Pen	Adalimumab	138	3,864	$997,950
Cosentyx Sensoready (2 Pens)	Secukinumab	57	1,596	$423,600
Skyrizi Pen	Risankizumab-Rzaa	17	1,318	$371,135

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$1,203	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Zarmeena Ali, MD?

Tedicare shows public-source Medicare data for Zarmeena Ali, MD (NPI 1538137708), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Zarmeena Ali, MD have ACO affiliation data?

Zarmeena Ali, MD is shown with ACO affiliation data for Southeastern Health Partners (MSSP, ACO ID A3325).

What billing organization is linked to Zarmeena Ali, MD?

Zarmeena Ali, MD is linked to ARTICULARIS HEALTHCARE GROUP INC. (billing NPI 1730770421) in the available physician profile data.

Does Zarmeena Ali, MD have Open Payments data?

Zarmeena Ali, MD has 56 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.